LGG-09. A Nationwide Service Evaluation of Safety, Radiologic and Visual Outcome Refining Bevacizumab-based Treatments in Children with Progressive Low-Grade Glioma

INTRODUCTION: Bevacizumab/Irinotecan is currently 3rd-line treatment in the UK for progressive Paediatric Low-Grade Glioma (PLGG) based on limited evidence. A nationwide service evaluation was conducted to review its safety and efficacy amongst a larger cohort. METHODS: Data from children with PLGG...

Descripción completa

Detalles Bibliográficos
Autores principales: Green, Katherine, Panagopoulou, Paraskevi, D’Arco, Felice, O'Hare, Patricia, Bowman, Richard, Walters, Bronwen, Dahl, Christine, Jorgensen, Mette, Patel, Pritesh, Slater, Olga, Ahmed, Rehana, Bailey, Simon, Carceller, Fernando, Collins, Rhiannon, Corley, Elizabeth, English, Martin, Hayden, James, Howells, Lisa, Kamal, Ahmed, Kilday, John Paul, Lowis, Stephen, Lumb, Blanche, Micic, Thomas, Mitra, Dip, Pace, Erika, Picton, Susan, Pizer, Barry, Shafiq, Ayad, Uzunova, Lena, Wilson, Shaun, Wayman, Harriet, Hargrave, Darren, Opocher, Enrico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Low Grade Glioma
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164923/
http://dx.doi.org/10.1093/neuonc/noac079.325

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164923/
http://dx.doi.org/10.1093/neuonc/noac079.325

Ejemplares similares